Cancer Research and Treatment

Original Article

Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis: Ha-young Lee, Sang Joon Shin, Hyo Song Kim, Soo Jung Hong, Jung Woo Han, Seung Taek Lim, Jae Kyung Roh, Sun Young Rha; Cancer Res Treat. 2012;44(1):43-49. Published online March 31, 2012; DOI: https://doi.org/10.4143/crt.2012.44.1.43

PURPOSE
The combination of gemcitabine and docetaxel (GD) is used to effectively treat patients with soft tissue sarcoma (STS). It is widely considered that the conventional doses used are too high for long term use and many patients must discontinue GD treatment due to its toxicity. Therefore, to determine the appropriate dose meeting acceptable efficacy results, while minimizing toxic side effects, we treated patients with a weekly infusion of GD (weekly GD).
MATERIALS AND METHODS
A total of 22 patients presenting a variety of STSs were treated at Yonsei Cancer Center. All patients had metastatic or recurrent cancer and had previously received doxorubicin and ifosfamide combination chemotherapy. In all cases, gemcitabine (1,000 mg/m2) and docetaxel (35 mg/m2) were administered intravenously on days 1 and 8 of a 21-day cycle. We retrospectively reviewed the medical records of these patients.
RESULTS
The response rate was 4.5%, with one patient diagnosed with leiomyosarcoma having a partial response, and the disease control rate was 40.9%. The median progression-free survival (PFS) duration was 2.7 months and the PFS was correlated with the treatment response to a weekly GD. The median overall survival (OS) duration was 7.8 months and the OS was correlated with histology. There was no significant difference in OS between patients who received weekly GD as a 2nd line chemotherapy and those who received 3rd line or more. Treatment was generally well tolerated.
CONCLUSION
Weekly GD was well tolerated and showed moderate efficacy, indicating that this could be a reasonable option as a salvage treatment for metastatic STS.

Citations

Citations to this article as recorded by

Comparative Evaluation of Second-Line Chemotherapy Agents for Advanced Soft Tissue Sarcoma: Gemcitabine/Docetaxel, Pazopanib, and Alternatives
Tae Hun Kim, Ki Hyuk Sung, So Hak Chung
Journal of the Korean Orthopaedic Association.2024; 59(1): 22. CrossRef
当科における再発・進行骨軟部肉腫に対するゲムシタビン＋ドセタキセル療法の使用経験
悠太久保田, 正典河野, 達也岩﨑, 一朗糸永, 信広加来, 弘津村, 和宏田仲
Orthopedics & Traumatology.2024; 73(2): 292. CrossRef
Primary pleomorphic leiomyosarcoma of descending mesocolon
Suhaildeen Kajamohideen, Balasubramanian Venkitaraman, Sathyanarayanan M Shivkumaran, Prithviraj Premkumar
Formosan Journal of Surgery.2021; 54(5): 196. CrossRef
Surgical resection of leiomyosarcoma of the inferior vena cava: A case series and literature review
Maggie Zhou, Christopher Javadi, Greg W. Charville, Nam Q. Bui, E John Harris, George A. Poultsides, Jeffrey A. Norton, Brendan Visser, Byrne Lee, Monica M. Dua, Kristen N. Ganjoo
Surgical Oncology.2021; 39: 101670. CrossRef
Stabilization of Metastatic Uterine Leiomyosarcoma Using Pembrolizumab
Katherine Cotangco, Mary Meram, M. Patrick Lowe
Journal of the National Comprehensive Cancer Network.2020; 18(8): 1012. CrossRef
Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study
Hitomi Hara, Teruya Kawamoto, Naomasa Fukase, Yohei Kawakami, Toshiyuki Takemori, Shuichi Fujiwara, Kazumichi Kitayama, Kotaro Nishida, Ryosuke Kuroda, Toshihiro Akisue
BMC Cancer.2019;[Epub] CrossRef
Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study
Yunjung Choi, Mi Sun Yun, Sang Hee Lim, Jeeyun Lee, Jin-Hee Ahn, Yu Jung Kim, Kyong Hwa Park, Young Suk Park, Ho Yeong Lim, Hyonggin An, Dong-Churl Suh, Yeul Hong Kim
Cancer Research and Treatment.2018; 50(1): 175. CrossRef
Establishment and characterization of a canine soft tissue sarcoma patient‐derived xenograft model
J. P. Frazier, E. Beirne, S. H. Ditzler, I. Tretyak, J. R. Casalini, D. J. Thirstrup, S. Knoblaugh, J. G. Ward, C. D. Tripp, R. A. Klinghoffer
Veterinary and Comparative Oncology.2017; 15(3): 754. CrossRef
Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients
Kazuhiro Tanaka, Susumu Joyama, Hirokazu Chuman, Hiroaki Hiraga, Hideo Morioka, Hideki Yoshikawa, Masami Hosaka, Mitsuru Takahashi, Tadahiko Kubo, Hiroshi Hatano, Mitsunori Kaya, Junya Toguchida, Yoshihiro Nishida, Akihito Nagano, Hiroshi Tsumura, Yukihid
World Journal of Surgical Oncology.2016;[Epub] CrossRef
A Phase II Study of Gemcitabine, Vincristine, and Cisplatin (Gvp) As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma
Zhiguo Luo, Xiaowei Zhang, Wei Peng, Xianghua Wu, Huijie Wang, Hui Yu, Jialei Wang, Jianhua Chang, Xiaonan Hong
Medicine.2015; 94(43): e1777. CrossRef
Emerging therapies for adult soft tissue sarcoma
Stefano Radaelli, Sivia Stacchiotti, Paolo G Casali, Alessandro Gronchi
Expert Review of Anticancer Therapy.2014; 14(6): 689. CrossRef
A Randomized Phase II/III Trial of Perioperative Chemotherapy with Adriamycin Plus Ifosfamide Versus Gemcitabine Plus Docetaxel for High-grade Soft Tissue Sarcoma: Japan Clinical Oncology Group Study JCOG1306
K. Kataoka, K. Tanaka, J. Mizusawa, A. Kimura, H. Hiraga, A. Kawai, T. Matsunobu, A. Matsumine, N. Araki, Y. Oda, H. Fukuda, Y. Iwamoto
Japanese Journal of Clinical Oncology.2014; 44(8): 765. CrossRef
Docetaxel-associated palmar-plantar erythrodysesthesia: A case report and review of the literature
Christy S Harris, Dorothy Wang, Alison Carulli
Journal of Oncology Pharmacy Practice.2014; 20(1): 73. CrossRef
Gemcitabine and Docetaxel for Metastatic Soft Tissue Sarcoma - a Single Center Experience
Thomas Schmitt, Florentina Kosely, Patrick Wuchter, Johann-Wilhelm Schmier, Anthony D. Ho, Gerlinde Egerer
Oncology Research and Treatment.2013; 36(7-8): 415. CrossRef

12,240 View
68 Download
14 Crossref

First
Prev
Page of 1
Next
Last

Search